Attorney Docket No.: 6568.200-US

PATENT:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Conde-Frieboes et al.

Serial No.: 10/719,110

Group Art Unit: To be assigned

Filed: November 21, 2003

Examiner: To be assigned

For: Compounds and Compositions for Treating Obesity

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

- 1. Information Disclosure Statement
- 2. Form PTO-1449
- 3. Copy of References (5)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on January 20, 2004

Dolly Kapadia

(name of person mailing paper)

(signature of person mailing paper)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Conde-Frieboes et al.

Application No.: 10/719,110

Group Art Unit: To be assigned

Filed: November 21, 2003

Examiner: To be assigned

For: Compounds and Compositions for Treating Obesity

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

- 1. Huszar et al., Cell, Vol. 88, pages 131-141 (1997)
- 2. Klebig et al., Proc. Natl., Acad. Sci. USA, Vol. 92, pages 4728-4732 (1995)
- 3. Vaisse et al., Nature Genetics, Vol. 20, pages 113-114 (1998)

4. Vergoni et al., European Journal of Pharmacology, Vol. 179, pages 347-355 (1990)

5. Yeo et al., Nature Genetics, Vol. 20, pages 111-112 (1998)

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed within three months of the filing date of a national application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, or before the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Pharmaceuticals, Inc. Deposit Account No. 14-1447.

Date: January 20, 2004

Rosemarie R. Wilk Orescan, Reg. No. 45,220

Novo Nordisk Pharmaceuticals, Inc.

100 College Road West Princeton, NJ 08540 (609) 987-5800

Respectfully submitted

Use the following customer number for all correspondence regarding this application.

23650
PATENT TRADEMARK OFFICE

| FORM PTO-1449 (Rev 12-321 | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | Atty. Docket No. 6568.200-US | | Serial No. 10/719,110 | | |
|------------------------------|--|---|---|------------------------------|----------------------|-------------------------------|----------|--|
| ेंद्री | INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | Applicant Conde-Frieboes et al. | | | | | |
| AN 2 2 2004 3 | (Use several sheets if necessary) | | Filing Date November 21, 2003 | | Group To be assigned | | | |
| a de | | U.S. PATE | NT DOCUMENTS | | <u> </u> | | | |
| EXAMINER INITIAL | DOCUMENT NUMBER | DOCUMENT | | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE | | |
| | | | | | 1 | | | |
| - | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | FOREIGN PATENT DOCUMENTS | | | | | | | |
| | DOCUMENT | | ; · | | | TRANS | LATION | |
| | NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | YES | NO | |
| | * | | | | | | | |
| | | | | | | | | |
| | | | - | | | | | |
| | | | | | | | | |
| T | | | Author, Title, Date, Pertinologies 131-141 (199 | | c.) | | <u> </u> | |
| | | , ,, <u></u> , <u></u> | Bez (->> | ^ | | | | |
| | Klebig et al., | Klebig et al., Proc. Natl., Acad. Sci. USA, Vol. 92, pages 4728-4732 (1995) | | | | | | |
| | Vaisse et al., | Vaisse et al., Nature Genetics, Vol. 20, pages 113-114 (1998) | | | | | | |
| | Vergoni et al | Furonean Iour | nal of Pharmacolog | v Vol 1 | 70 nages 34 | 7-355 (1 | 990) | |
| | vergom et al. | , Daropean Jour | | | | , 555 (1 | | |
| | Yeo et al., Nature Genetics, Vol. 20, pages 111-112 (1998) | | | | | | | |
| | | | | | | | | |
| | | | <u> </u> | | | | | |
| EXAMINER | | | DATE CONSIDERED | | | | | |

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.